SCIENCE & TECHNOLOGY
CA
Merck licenses investigational monthly HIV-prevention medicine

Merck announced royalty-free voluntary licensing agreements for alimatravir, also called MK-8527.
The once-monthly oral medicine is being studied for HIV pre-exposure prophylaxis and remains investigational.
The access plan involves seven manufacturers, including Aurobindo Pharma, Cipla, Emcure Pharmaceuticals and Viatris; licensing is distinct from regulatory approval.
The once-monthly oral medicine is being studied for HIV pre-exposure prophylaxis and remains investigational.
The access plan involves seven manufacturers, including Aurobindo Pharma, Cipla, Emcure Pharmaceuticals and Viatris; licensing is distinct from regulatory approval.
Key Facts / Static GK
PrEP: Pre-Exposure Prophylaxis.
HIV: Human Immunodeficiency Virus.
Merck is known as MSD outside the United States and Canada.
HIV: Human Immunodeficiency Virus.
Merck is known as MSD outside the United States and Canada.
Practice Quiz — 28 July 2026
Q1. Merck's alimatravir (MK-8527) is being studied as a monthly oral medicine for what?
Answer: (C) HIV pre-exposure prophylaxis — It remains investigational; seven manufacturers got royalty-free voluntary licences.

A LITTLE PRACTICE. EVERY DAY.
Turn your reading into practice.
Daily current affairs, quizzes, vocabulary and a mistake bank — together in PrepZen.
Free Android app · Learn at your own pace
STAY IN THE STUDY LOOP
Good notes. One tap away.
Find study reels, PDF keywords and current affairs updates from PrepZen.